ClinicalTrials.gg
RecruitingNCT07625215CARDIOVERTUpdated Oct 20, 2026

A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation

A Phase 2 interventional study of BAY 3670549 and Placebo in Atrial Fibrillation, sponsored by Bayer. Recruiting at 30 sites in 8 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 20, 2026Site recruiting status changedStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Atrial Fibrillation by Bayer — 1 open to participants now, 1 under way, none of them phase 3. Atrial Fibrillation · Bayer.

Planned enrollment
5th of 13
360 · median 100
Started
2026
the only one that year
Phase 2
6 of 64
1 open now
Registered
64th of 64
by date

Among the 64 studies in Atrial Fibrillation by Bayer, this one is the 5th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2026, is one of 6 in phase 2, and was the 64th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

1 of the 64 studies in Atrial Fibrillation by Bayer is open now, in 8 countries.

By country, each count listing its studies:

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Atrial Fibrillation by Bayer, or all of them as a file.
02

Study summary

The main goal of this study is to find out how well BAY 3670549 works, how safe it is, how well people can tolerate it, and how the body handles the medicine. The study will compare BAY 3670549 to a placebo (a dummy treatment with no active medicine) in people with AF who need a treatment called electrical cardioversion.

Electrical cardioversion is a procedure that helps the heart return to a normal rhythm. In this study, each participant will get a single intravenous (IV) infusion of either BAY 3670549 or a placebo. Participants will then be observed to see whether the heart rhythm returns to a normal rhythm. If it does not, electrical cardioversion can still be performed as planned. The study will look at how many participants return from AF to a normal rhythm, without needing electrical cardioversion and how long it takes. It will also show how many participants experience medical problems after treatment and how BAY 3670549 move into, through and out of the participants' body.

The total duration of the study for an individual participant may be up two months.

The findings from this study may contribute to the development of a new treatment option for people with AF.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 85 years of age inclusive, at the time of signing the .
  • Participant is hemodynamically stable and does not require emergency cardioversion, as determined by the investigator.
  • Participant has a current episode of atrial fibrillation (AF) ongoing for at least 3 hours and no more than 30 days at the time of randomization.
  • Participant has an indication for electrical cardioversion of AF, as determined by the investigator according to standard clinical practice and national/institutional guidelines.
  • At randomization, successful initiation and achievement of therapeutic levels of anticoagulation therapy, as well as completion of imaging evaluation for left atrial thrombi, as appropriate for the duration of the AF episode and risk for the participant according to national guideline and institution-specific routine practice.
  • within range [18 - 39.9] kg/m2.
  • use by participants or participant partners should be consistent with the study protocol and local regulations regarding the methods of contraception for those participating in clinical studies.
  • Signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
  • Willing and able to comply with the receipt, home use, and return of the continuous recording device, as well as with the participation in scheduled telephone follow-up assessments.

Exclusion criteria

Exclusion Criteria:

  • Current atrial flutter (AFL) or combined AF/AFL
  • for electrical cardioversion on planned treatment day
  • Documented severely dilated left atrium (left atrial diameter, LAD >5 cm) measured by any modality within the 6 months prior to screening; if several values are available, the most recent one shall be reported. If left atrium diameter was not measured in the last 6 months or a major cardiovascular event occurred within the last 6 months, a new measurement must be done at screening
  • Unsuccessful conversion of current AF episode (pharmacologically or electrically)
  • Known severe valvular heart disease (e.g., severe mitral regurgitation, severe aortic stenosis)
  • Patients with Class ≥ III heart failure, or with active management of acute heart failure decompensation on treatment day.
  • History within the preceding 3 months prior to randomization of any of the following events, or any other significant cardiovascular event as judged by the investigator:

    • Stroke
    • Myocardial infarction
    • Unstable angina pectoris or other signs of myocardial ischemia
    • Cardiac surgery
    • Transcatheter valve replacement
    • Percutaneous coronary intervention (PCI)
    • Coronary artery bypass graft (CABG) or other revascularization procedure
  • Severe renal impairment, i.e., estimated (eGFR) \<30 mL/min/1.73m² (using CKD-EPI formula) or requiring dialysis
  • Severe hepatic impairment, i.e. Class C
  • Use of anti-arrhythmic class I or III drugs within 5 half-lives before study drug administration (oral amiodarone in the previous 3 months)
  • Hypertension with SBP ≥ 180 mmHg or hypotension (SBP \< 90 mmHg) at randomization (based on the second BP measurement)
  • Stressor-associated AF, i.e., in the setting of an acute and reversible stressor (e.g., cardiac surgery, myocarditis, endocarditis, sepsis, pneumonia, etc.). This includes ablation procedure within the preceding one month prior to randomization.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    BAY 3670549

    Drug: BAY 3670549

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • DrugBAY 3670549

    intravenous (IV) treatment

  • OtherPlacebo

    intravenous (IV) treatment

06

What researchers measure

Primary outcomes

  1. Number of Participants with conversion from atrial fibrillation (AF) to sinus rhythm (SR), sustained for ≥1 minute, within 3 hours after start of study intervention administration, and prior to use of rescue therapy or other SoC for cardioversion

    AF = atrial fibrillation ; SR = sinus rhythm ; SoC = Standard of Care;

    Time frame: Up to 3 hours after start of administration of study intervention

Secondary outcomes

  1. Number of Participants who experienced Treatment Emergent Adverse Events (TEAE)s

    TEAE = Treatment Emergent Adverse Events; \*Pre-dose: Within 4 hours prior to study intervention administration

    Time frame: From pre-dose* up to 48 hours after start of administration of study intervention

  2. Time to conversion from AF to SR as defined in the primary endpoint

    AF = atrial fibrillation SR = sinus rhythm;

    Time frame: Up to 3 hours after start of administration of study intervention

  3. Number of Participants in SR, at 3 hours after start of study intervention administration without prior use of rescue therapy or other SoC for cardioversion

    SoC = Standard of Care;

    Time frame: Up to 3 hours after start of administration of study intervention

  4. Plasma concentration of BAY 3670549 at the end of the infusion

    \*Pre-dose: Within 4 hours prior to study intervention administration

    Time frame: From pre-dose* up to 8 hours after start of administration of study intervention

07

Study locations

9 of 30 sites recruiting
  • UCSF Advanced Heart Failure Comprehensive Care Center
    San Francisco, California 94143, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • UCHealth University of Colorado Hospital - Cardiology
    Aurora, Colorado 80045, United States
    Not yet recruiting
  • Massachusetts General Hospital - Cardiology
    Boston, Massachusetts 02114, United States
    Not yet recruiting
  • Henry Ford Hospital - Cardiology
    Detroit, Michigan 48202, United States
    Recruiting
  • M Health Fairview Heart Clinic - Maplewood
    Maplewood, Minnesota 55109, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Duke University Hospital - Cardiology
    Durham, North Carolina 27704, United States
    Not yet recruiting
  • Texas Health Heart and Vascular Specialists - Fort Worth
    Fort Worth, Texas 76104, United States
    Not yet recruiting
  • CHRISTUS Trinity | Mother Frances Louis and Peaches Owen Heart Hospital - Electrophysiology Clinic
    Tyler, Texas 75701, United States
    Not yet recruiting
  • UZ Leuven Gasthuisberg - Cardiology diseases department
    Leuven, Flemish Brabant 3000, Belgium
    Recruiting
  • Jessa Ziekenhuis | Hartcentrum Hasselt
    Hasselt, Limburg 3500, Belgium
    Not yet recruiting
  • AZ Delta | Clinical Trial Center - Cardiology
    Roeselare, West Flanders 8800, Belgium
    Not yet recruiting
  • University Multiprofile Hospital For Active Treatment Sveti Georgi' - EAD Department of Intensive Cardiology"
    Plovdiv, Plovdiv Province 4001, Bulgaria
    Not yet recruiting
  • Multiprofile Hospital for Active Treatment Knyaginya Klementina Sofia EAD | Cardiology Department
    Sofia, Sofia City Province 1233, Bulgaria
    Not yet recruiting
  • University Hospital for Active Treatment Tsaritsa Joanna - ISUL | Cardiology Clinic
    Sofia, Sofia City Province 1527, Bulgaria
    Recruiting
  • Multiprofile Hospital for Active Treatment Dr. Stefan Cherkezov | Base 1 - Cardiology Department
    Veliko Tarnovo, Veliko Tarnovo Province 5000, Bulgaria
    Recruiting
  • Medizinische Hochschule Hannover|Kardiologie und Angiologie
    Hanover, Lower Saxony 30625, Germany
    Not yet recruiting
  • Herz-und Diabeteszentrum NRW|Elektrophysiologie/Rhythmologie
    Bad Oeynhausen, North Rhine-Westphalia 32545, Germany
    Not yet recruiting
  • Klinikum Altenburger Land GmbH-Klinik für Kardiologie, Pneumologie und Internistische Intensivmedizin
    Altenburg, Thuringia 04600, Germany
    Recruiting
  • Tolna Vármegyei Balassa János Kórház - I. Belgyógyászati Osztály: Kardiológia, Nefrológia
    Szekszárd, Tolna County 7100, Hungary
    Not yet recruiting
  • Semmelweis Egyetem, Varosmajori Sziv- és Ergyogyaszati Klinika
    Budapest, 1122, Hungary
    Recruiting
  • Ente Ecclesiastico Ospedale Generale Regionale Miulli - Cardiologia e UTIC
    Acquaviva delle Fonti, Apulia 70021, Italy
    Recruiting
  • Azienda Ospedaliero-Universitaria Policlinico Umberto I - Malattie Cardiovascolari
    Rome, Lazio 00161, Italy
    Not yet recruiting
  • Centro Cardiologico Monzino S.p.A. - UO Scompenso e Cardiologia Clinica
    Milan, Lombardy 20138, Italy
    Recruiting
  • Azienda Ospedaliero Universitaria Delle Marche - Clinica di Cardiologia e Aritmologia
    Torrette, The Marches 60126, Italy
    Not yet recruiting
  • Maastricht UMC
    Maastricht, Limburg 6229 HX, Netherlands
    Not yet recruiting
  • Universitair Medisch Centrum Groningen
    Groningen, 9713 GZ, Netherlands
    Not yet recruiting
  • American Heart of Poland S.A. - MCSN, PAKS w Chrzanowie - Oddział Intensywnej Opieki Kardiologicznej
    Chrzanów, Lesser Poland Voivodeship 32-500, Poland
    Not yet recruiting
  • USK nr 4 w Lublinie - Kliniczny Odd. Kardiologii, Reh. Kardio., Ch. Wew. z Pododdzialem Intensywnej Opieki Kardio.
    Lublin, Lublin Voivodeship 20-090, Poland
    Not yet recruiting
  • Samodzielny Publiczny Specjalistyczny Szpital Zachodni im. sw. Jana Pawla II
    Grodzisk Mazowiecki, Masovian Voivodeship 05-825, Poland
    Recruiting
  • American Heart of Poland S.A. - PAKS Centrum Kardiologii i Kardiochirurgii w Bielsku-Białej - Oddział Kardiologii
    Bielsko-Biala, Silesian Voivodeship 43-316, Poland
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for May 2030, 44 months after the start.

Of 41 phase 2 interventional studies under Atrial Fibrillation, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's planned 44 months is above that.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2026
First posted
Jun 4, 2026
StartActual
Sep 1, 2026was Aug 2026
Primary completionEst.
May 16, 2030
CompletionEst.
May 16, 2030
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added, 8 sites removed. 6 sites changed recruiting status (6 now recruiting)
Show 6 sites
  • Unnamed siteWithdrawn→Recruiting
  • UZ Leuven Gasthuisberg - Cardiology diseases department · Leuven, BelgiumNot yet recruiting→Recruiting
  • Klinikum Altenburger Land GmbH-Klinik für Kardiologie, Pneumologie und Internistische Intensivmedizin · Altenburg, GermanyNot yet recruiting→Recruiting
  • Ente Ecclesiastico Ospedale Generale Regionale Miulli - Cardiologia e UTIC · Acquaviva delle Fonti, ItalyNot yet recruiting→Recruiting
  • Henry Ford Hospital - Cardiology · Detroit, United StatesNot yet recruiting→Recruiting
  • Semmelweis Egyetem, Varosmajori Sziv- és Ergyogyaszati Klinika · Budapest, HungaryNot yet recruiting→Recruiting
Show 9 added (4 Italy, 4 Poland, 1 United States)
  • M Health Fairview Heart Clinic - Maplewood · Maplewood, United States
  • Ente Ecclesiastico Ospedale Generale Regionale Miulli - Cardiologia e UTIC · Acquaviva delle Fonti, Italy
  • Azienda Ospedaliero-Universitaria Policlinico Umberto I - Malattie Cardiovascolari · Rome, Italy
  • Centro Cardiologico Monzino S.p.A. - UO Scompenso e Cardiologia Clinica · Milan, Italy
  • Azienda Ospedaliero Universitaria Delle Marche - Clinica di Cardiologia e Aritmologia · Torrette, Italy
  • American Heart of Poland S.A. - MCSN, PAKS w Chrzanowie - Oddział Intensywnej Opieki Kardiologicznej · Chrzanów, Poland
  • USK nr 4 w Lublinie - Kliniczny Odd. Kardiologii, Reh. Kardio., Ch. Wew. z Pododdzialem Intensywnej Opieki Kardio. · Lublin, Poland
  • Samodzielny Publiczny Specjalistyczny Szpital Zachodni im. sw. Jana Pawla II · Grodzisk Mazowiecki, Poland
  • American Heart of Poland S.A. - PAKS Centrum Kardiologii i Kardiochirurgii w Bielsku-Białej - Oddział Kardiologii · Bielsko-Biala, Poland
Show 8 removed
  • Ente Ecclesiastico Ospedale Generale Regionale Miulli - Cardiologia e UTIC · Acquaviva delle Fonti, Italy
  • Centro Cardiologico Monzino S.p.A. - UO Scompenso e Cardiologia Clinica · Milan, Italy
  • Azienda Ospedaliero-Universitaria Policlinico Umberto I - Malattie Cardiovascolari · Roma, Italy
  • Azienda Ospedaliero Universitaria Delle Marche - Clinica di Cardiologia e Aritmologia · Torrette, Italy
  • American Heart of Poland S.A. - PAKS Centrum Kardiologii i Kardiochirurgii w Bielsku-Białej - Oddział Kardiologii · Bielsko-Biala, Poland
  • American Heart of Poland S.A. - MCSN, PAKS w Chrzanowie - Oddział Intensywnej Opieki Kardiologicznej · Chrzanów, Poland
  • Samodzielny Publiczny Specjalistyczny Szpital Zachodni im. sw. Jana Pawla II · Grodzisk Mazowiecki, Poland
  • USK nr 4 w Lublinie - Kliniczny Odd. Kardiologii, Reh. Kardio., Ch. Wew. z Pododdzialem Intensywnej Opieki Kardio. · Lublin, Poland
across 2 updates, Oct 6, 2026 – Oct 20, 2026
Start date
Aug 18, 2026→Sep 1, 2026
Oct 6, 2026
Show all 2 updates
  1. Oct 20, 2026
    8 sites added, 8 sites removed. 4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • Henry Ford Hospital - Cardiology · Detroit, United StatesNot yet recruiting→Recruiting
    • Unnamed siteNot yet recruiting→Recruiting
    • Unnamed siteNot yet recruiting→Recruiting
    • Semmelweis Egyetem, Varosmajori Sziv- és Ergyogyaszati Klinika · Budapest, HungaryNot yet recruiting→Recruiting
    Show 8 added (4 Italy, 4 Poland)
    • Ente Ecclesiastico Ospedale Generale Regionale Miulli - Cardiologia e UTIC · Acquaviva delle Fonti, Italy
    • Azienda Ospedaliero-Universitaria Policlinico Umberto I - Malattie Cardiovascolari · Rome, Italy
    • Centro Cardiologico Monzino S.p.A. - UO Scompenso e Cardiologia Clinica · Milan, Italy
    • Azienda Ospedaliero Universitaria Delle Marche - Clinica di Cardiologia e Aritmologia · Torrette, Italy
    • American Heart of Poland S.A. - MCSN, PAKS w Chrzanowie - Oddział Intensywnej Opieki Kardiologicznej · Chrzanów, Poland
    • USK nr 4 w Lublinie - Kliniczny Odd. Kardiologii, Reh. Kardio., Ch. Wew. z Pododdzialem Intensywnej Opieki Kardio. · Lublin, Poland
    • Samodzielny Publiczny Specjalistyczny Szpital Zachodni im. sw. Jana Pawla II · Grodzisk Mazowiecki, Poland
    • American Heart of Poland S.A. - PAKS Centrum Kardiologii i Kardiochirurgii w Bielsku-Białej - Oddział Kardiologii · Bielsko-Biala, Poland
    Show 8 removed
    • Ente Ecclesiastico Ospedale Generale Regionale Miulli - Cardiologia e UTIC · Acquaviva delle Fonti, Italy
    • Centro Cardiologico Monzino S.p.A. - UO Scompenso e Cardiologia Clinica · Milan, Italy
    • Azienda Ospedaliero-Universitaria Policlinico Umberto I - Malattie Cardiovascolari · Roma, Italy
    • Azienda Ospedaliero Universitaria Delle Marche - Clinica di Cardiologia e Aritmologia · Torrette, Italy
    • American Heart of Poland S.A. - PAKS Centrum Kardiologii i Kardiochirurgii w Bielsku-Białej - Oddział Kardiologii · Bielsko-Biala, Poland
    • American Heart of Poland S.A. - MCSN, PAKS w Chrzanowie - Oddział Intensywnej Opieki Kardiologicznej · Chrzanów, Poland
    • Samodzielny Publiczny Specjalistyczny Szpital Zachodni im. sw. Jana Pawla II · Grodzisk Mazowiecki, Poland
    • USK nr 4 w Lublinie - Kliniczny Odd. Kardiologii, Reh. Kardio., Ch. Wew. z Pododdzialem Intensywnej Opieki Kardio. · Lublin, Poland
    + 1 other change: verification date
  2. Oct 6, 2026
    1 site added. 4 sites changed recruiting status (3 now recruiting, 1 now not yet recruiting)
    Show 4 sites
    • Unnamed siteWithdrawn→Not yet recruiting
    • UZ Leuven Gasthuisberg - Cardiology diseases department · Leuven, BelgiumNot yet recruiting→Recruiting
    • Klinikum Altenburger Land GmbH-Klinik für Kardiologie, Pneumologie und Internistische Intensivmedizin · Altenburg, GermanyNot yet recruiting→Recruiting
    • Ente Ecclesiastico Ospedale Generale Regionale Miulli - Cardiologia e UTIC · Acquaviva delle Fonti, ItalyNot yet recruiting→Recruiting
    Show site
    • M Health Fairview Heart Clinic - Maplewood · Maplewood, United States
    Start date Aug 18, 2026→Sep 1, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07625215
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jun 4, 2026
Start date
Sep 1, 2026
Primary completion
May 16, 2030 (estimated)
Completion
May 16, 2030 (estimated)
Last update
Oct 20, 2026

Study contacts

Bayer Clinical Trials Contact
Contact
clinical-trials-contact@bayer.com
18888422937

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion